Saba Capital Management’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Saba Capital Management’s Portfolio SLXNW Stock Details SLXNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$242	Hold	11,937	–	–	﹤0.01%	389
2025 Q4	$318	Hold	11,937	–	–	﹤0.01%	350
2025 Q3	$421	Hold	11,937	–	–	﹤0.01%	329
2025 Q2	$488	Hold	11,937	–	–	﹤0.01%	322
2025 Q1	$835	Hold	11,937	–	–	﹤0.01%	266
2024 Q4	$488	Hold	11,937	–	–	﹤0.01%	285
2024 Q3	$606	Buy	+11,937	New	+$691	﹤0.01%	355

Other funds holding SLXNW

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

SBLIC

Security Benefit Life Insurance Company Topeka, Kansas $190M AUM 36.38% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

Saba Capital Management's SLXNW Position: Q1 2026 in Review

Saba Capital Management held its Silexion Therapeutics Warrant (SLXNW) position steady in Q1 2026 at 11,937 shares worth $242. The position accounts for ﹤0.01% of the portfolio, ranked #389.

Saba Capital Management first reported a position in SLXNW in Q3 2024 and has held it in 7 quarters since. The position peaked at $835 in Q1 2025. 19 funds tracked by Wall St. Rank hold SLXNW as of Q1 2026.

Saba Capital Management held 11,937 shares of Silexion Therapeutics Warrant worth $242 as of Q1 2026.
Saba Capital Management left its Silexion Therapeutics Warrant share count unchanged in Q1 2026.
Silexion Therapeutics Warrant made up ﹤0.01% of Saba Capital Management's portfolio in Q1 2026, its #389 holding.
Saba Capital Management first reported a position in Silexion Therapeutics Warrant in Q3 2024 and has held it in 7 quarters since.
Saba Capital Management's Silexion Therapeutics Warrant position peaked at $835 in Q1 2025.
19 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q1 2026.

Based on Saba Capital Management's 13F filing for Q1 2026, filed 15 May 2026.